Eptacog alfa biosimilar - AryoGen Pharmed

Drug Profile

Eptacog alfa biosimilar - AryoGen Pharmed

Alternative Names: AryoSeven

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AryoGen Biopharma
  • Developer AryoGen Pharmed
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Factor-VII-Deficiency; Haemophilia; Haemophilia A; Haemophilia B; Thrombasthenia

Most Recent Events

  • 21 Jan 2018 AryoGen Pharmed completes a phase III trial for Hemophilia A or B in Iran (IRCT2017021831193N2)
  • 23 Aug 2017 AryoGen Pharmed initiates enrolment in a phase III trial for Hemophilia A or B in Iran (IRCT2017021831193N2)
  • 21 Dec 2016 AryoGen Pharmed initiates enrolment in a phase III trial for Haemophilia A (In children, In adolescents, In adults) in Iran (IV) (IRCT2016120231193N1)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top